Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Majdi Halabi

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|January 22, 2013
Transthoracic delivery of large devices into the left ventricle through the right ventricle and interventricular septum: preclinical feasibilityMajdi Halabi, Kanishka Ratnayaka, Anthony Z Faranesh, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|July 25, 2022
Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registryOfer Kobo, Majdi Saada, Clemens von Birgelen, et al.
Plos One|June 18, 2021
Acute myocardial infarction in the Covid-19 era: Incidence, clinical characteristics and in-hospital outcomes-A multicenter registryAlexander Fardman, Doron Zahger, Katia Orvin, et al.
Journal of the American Heart Association|January 12, 2024
Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding RiskRan Kornowski, Maayan Konigstein, Michael Jonas, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
European Heart Journal|May 17, 2022
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysisMarco Valgimigli, Pieter C Smits, Enrico Frigoli, et al.
European Heart Journal|December 28, 2016
Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trialJozef Bartunek, Andre Terzic, Beth A Davison, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|January 22, 2013
Transthoracic delivery of large devices into the left ventricle through the right ventricle and interventricular septum: preclinical feasibilityMajdi Halabi, Kanishka Ratnayaka, Anthony Z Faranesh, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|July 25, 2022
Impact of multisite artery disease on clinical outcomes after percutaneous coronary intervention: an analysis from the e-Ultimaster registryOfer Kobo, Majdi Saada, Clemens von Birgelen, et al.
Plos One|June 18, 2021
Acute myocardial infarction in the Covid-19 era: Incidence, clinical characteristics and in-hospital outcomes-A multicenter registryAlexander Fardman, Doron Zahger, Katia Orvin, et al.
Journal of the American Heart Association|January 12, 2024
Percutaneous Coronary Interventions Using a Ridaforolimus-Eluting Stent in Patients at High Bleeding RiskRan Kornowski, Maayan Konigstein, Michael Jonas, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
European Heart Journal|May 17, 2022
Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysisMarco Valgimigli, Pieter C Smits, Enrico Frigoli, et al.
European Heart Journal|December 28, 2016
Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trialJozef Bartunek, Andre Terzic, Beth A Davison, et al.
Pageof 5